2024-12-08 - Analysis Report
## Merck & Co Inc (MRK) Stock Review

**1. Performance Relative to S&P 500 (VOO):**

Merck & Co Inc (MRK) is a leading pharmaceutical company known for its diverse portfolio of prescription medicines, vaccines, and animal health products.

The cumulative return for MRK is 69.40%, while the S&P 500 (VOO) shows a cumulative return of 122.19%.  Therefore, MRK underperformed VOO by 52.8 percentage points as of the last data point.  The relative underperformance, considering historical volatility, is at the 9.7th percentile (meaning it's relatively low compared to historical underperformance).  The provided alpha consistently shows negative values, suggesting underperformance relative to the market benchmark.  The beta values fluctuate significantly, implying varying sensitivities to market movements over the years.

**2. Recent Price Movement:**

* **Closing Price:** $103.09
* **5-Day Moving Average:** $102.09
* **20-Day Moving Average:** $100.15
* **60-Day Moving Average:** $106.47

The price is slightly above the 5-day and 20-day moving averages, suggesting short-term upward momentum. However, it is below the 60-day moving average, indicating a potential longer-term downward trend.

**3. Technical Indicators and Expected Return:**

* **RSI:** 72.48 –  Approaching overbought territory (generally considered above 70).  This suggests potential short-term price correction.
* **PPO:** 0.78 – Positive value indicates upward momentum.
* **20-Day Relative Divergence:** +0.6 – Short-term upward trend.
* **Expected Return:** 0.0% –  The provided expected return of 0% indicates no expected outperformance against the S&P 500 over the long term (2+ years) based on the available data.  A 0% expected return does not indicate a poor investment, but rather a neutral projection against the benchmark.

**4. Recent Earnings Analysis:**

The provided earnings data shows some variability in EPS and revenue. While revenue shows general growth, EPS fluctuates.  There is no information provided to assess whether these results beat or missed expectations.  A more comprehensive analysis would require access to analyst estimates.

* **Latest Quarterly Results:** Revenue slightly decreased compared to previous quarters.  EPS also experienced fluctuations.
* **Revenue Growth Trends:**  Generally increasing, but with some quarter-to-quarter variation.
* **EPS Trends:**  Fluctuating, not showing a clear upward or downward trend.


**5. Financial Information Analysis:**

* **Revenue and Profitability:** Revenue is relatively stable, showing moderate growth. Profit margins are generally high but show some fluctuation. The decrease in profit margin from Q1 2024 to Q2 2024 is noticeable.
* **Capital and Profitability:** Equity is increasing, though ROE is highly variable, indicating fluctuating profitability and efficiency in using shareholder equity. Negative ROE in Q4 2023 is a concerning indicator.


**6. News and Recent Issues:**

No recent news or market outlook is provided in the prompt.  Analyst opinions and performance highlights are also missing.  This section needs more information.

**7. Overall Analysis:**

MRK has demonstrated a lower cumulative return compared to the S&P 500 (VOO) over the period analyzed.  Technical indicators suggest short-term upward momentum, but the RSI is approaching overbought territory, hinting at potential near-term price correction.  Earnings data exhibits some variability in EPS and revenue growth, and profitability is fluctuating.  The negative alpha and fluctuating beta in the historical data suggest a consistently lower return compared to the market. The lack of recent news and analyst opinions limits a complete assessment.  A long-term investment strategy should carefully consider the consistently negative alpha and the volatility observed in the key financial metrics before making any investment decisions.

**8. Disclaimer:** This analysis is based solely on the data provided. It is not financial advice and should not be used as the sole basis for investment decisions.  Conduct thorough independent research and consult a financial advisor before making any investment choices.
